| |
N° Pts |
Accrual |
Rate AdenoCa |
Dose/Fx (Gy) |
Concurrent CT |
% pCR
(N° pts RTCT arm) |
3 yy OS %
[RTCT vsSurg] |
5 yy OS %
[RTCT vsSurg] |
Median SVV (mth)
[RTCT vsSurg] |
Median Fup (mth) |
| Walsh et al. [20] |
113 |
1990-1995 |
100% |
40/
2.7 |
CDDP + 5Fu |
25% (13/52) |
32 vs 6
(p=0.01) |
- |
16 vs 11 |
10
(0.1-59) |
| Urba et al. [21] |
100 |
1989-1994 |
75% |
45/
1.5 (twice daily) |
CDDP+ 5Fu+ Vimblastine |
28% (14/50) |
30 vs 16
(p=0.15) |
- |
16.9 vs 17.6 |
98.4
(72-118.8) |
| Burmeister et al. [24] |
256 |
1994-2000 |
62% |
35/
2.4 |
CDDP + 5Fu |
16%
(16/103) |
42 vs 36
(p=0.57) |
21 vs 19 |
22.2 vs 19.3 |
65
(0.4-120) |
| Tepper et al. [25] |
56 |
1997-2000 |
75% |
50.4/
1.8 |
CDDP + 5Fu |
40% (10/25) |
- |
39 vs 16 (p=0.002) |
53.8 vs 21.5 |
72
(NR) |
| Van Hagen et al. [26] |
366 |
2004-2008 |
75% |
41.2/
1.8 |
Carboplatin + Paclitaxel |
29%
(47/161) |
58 vs 44
(p=0.003) |
47 vs 34 |
49.4 vs 24 |
45.4
(25.5-80.9) |
|